DK3535290T3 - Manipuleret todelt celleindretning til opdagelse og karakterisering af t-celle-receptorinteraktion med beslægtet antigen - Google Patents
Manipuleret todelt celleindretning til opdagelse og karakterisering af t-celle-receptorinteraktion med beslægtet antigen Download PDFInfo
- Publication number
- DK3535290T3 DK3535290T3 DK17801380.1T DK17801380T DK3535290T3 DK 3535290 T3 DK3535290 T3 DK 3535290T3 DK 17801380 T DK17801380 T DK 17801380T DK 3535290 T3 DK3535290 T3 DK 3535290T3
- Authority
- DK
- Denmark
- Prior art keywords
- cognited
- engineered
- characterization
- antigen
- discovery
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1093—General methods of preparing gene libraries, not provided for in other subgroups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5156—Animal cells expressing foreign proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8518—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic expressing industrially exogenous proteins, e.g. for pharmaceutical use, human insulin, blood factors, immunoglobulins, pseudoparticles
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C12N2015/8527—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic for producing animal models, e.g. for tests or diseases
- C12N2015/859—Animal models comprising reporter system for screening tests
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Urology & Nephrology (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Computational Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Public Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201670874 | 2016-11-07 | ||
| PCT/EP2017/078474 WO2018083339A1 (en) | 2016-11-07 | 2017-11-07 | An engineered two-part cellular device for discovery and characterisation of t-cell receptor interaction with cognate antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3535290T3 true DK3535290T3 (da) | 2024-03-11 |
| DK3535290T5 DK3535290T5 (da) | 2024-09-02 |
Family
ID=57460293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17801380.1T DK3535290T5 (da) | 2016-11-07 | 2017-11-07 | Manipuleret todelt celleindretning til opdagelse og karakterisering af t-celle-receptorinteraktion med beslægtet antigen |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20200115432A1 (da) |
| EP (3) | EP3535290B1 (da) |
| JP (2) | JP7582779B2 (da) |
| KR (1) | KR102606929B1 (da) |
| CN (1) | CN110036026B (da) |
| AU (3) | AU2017352661B2 (da) |
| CA (1) | CA3039422A1 (da) |
| DK (1) | DK3535290T5 (da) |
| ES (1) | ES2970535T3 (da) |
| FI (1) | FI3535290T3 (da) |
| LT (1) | LT3535290T (da) |
| WO (1) | WO2018083339A1 (da) |
Families Citing this family (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11293021B1 (en) | 2016-06-23 | 2022-04-05 | Inscripta, Inc. | Automated cell processing methods, modules, instruments, and systems |
| CA3039420A1 (en) | 2016-11-07 | 2018-05-11 | Genovie Ab | A two-part device for t-cell receptor synthesis and stable genomic integration to tcr-presenting cells |
| CA3038917A1 (en) | 2016-11-07 | 2018-05-11 | Genovie Ab | An engineered multi-component system for identification and characterisation of t-cell receptors and t-cell antigens |
| US10011849B1 (en) | 2017-06-23 | 2018-07-03 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| US9982279B1 (en) | 2017-06-23 | 2018-05-29 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| HUE058668T2 (hu) | 2017-06-30 | 2022-09-28 | Inscripta Inc | Automatizált sejtkezelési eljárások, modulok, berendezések és rendszerek |
| WO2019200004A1 (en) | 2018-04-13 | 2019-10-17 | Inscripta, Inc. | Automated cell processing instruments comprising reagent cartridges |
| US10526598B2 (en) * | 2018-04-24 | 2020-01-07 | Inscripta, Inc. | Methods for identifying T-cell receptor antigens |
| US10508273B2 (en) | 2018-04-24 | 2019-12-17 | Inscripta, Inc. | Methods for identifying selective binding pairs |
| US10858761B2 (en) | 2018-04-24 | 2020-12-08 | Inscripta, Inc. | Nucleic acid-guided editing of exogenous polynucleotides in heterologous cells |
| AU2019292919A1 (en) | 2018-06-30 | 2021-03-11 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11142740B2 (en) | 2018-08-14 | 2021-10-12 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| US10532324B1 (en) | 2018-08-14 | 2020-01-14 | Inscripta, Inc. | Instruments, modules, and methods for improved detection of edited sequences in live cells |
| US11965154B2 (en) | 2018-08-30 | 2024-04-23 | Inscripta, Inc. | Detection of nuclease edited sequences in automated modules and instruments |
| EP3870697A4 (en) | 2018-10-22 | 2022-11-09 | Inscripta, Inc. | GMO ENZYMES |
| US11214781B2 (en) | 2018-10-22 | 2022-01-04 | Inscripta, Inc. | Engineered enzyme |
| US11001831B2 (en) | 2019-03-25 | 2021-05-11 | Inscripta, Inc. | Simultaneous multiplex genome editing in yeast |
| CN113631713A (zh) | 2019-03-25 | 2021-11-09 | 因思科瑞普特公司 | 酵母中的同时多重基因组编辑 |
| US10837021B1 (en) | 2019-06-06 | 2020-11-17 | Inscripta, Inc. | Curing for recursive nucleic acid-guided cell editing |
| WO2020257395A1 (en) | 2019-06-21 | 2020-12-24 | Inscripta, Inc. | Genome-wide rationally-designed mutations leading to enhanced lysine production in e. coli |
| US10927385B2 (en) | 2019-06-25 | 2021-02-23 | Inscripta, Inc. | Increased nucleic-acid guided cell editing in yeast |
| WO2021102059A1 (en) | 2019-11-19 | 2021-05-27 | Inscripta, Inc. | Methods for increasing observed editing in bacteria |
| KR20250033331A (ko) | 2019-12-10 | 2025-03-07 | 인스크립타 인코포레이티드 | 신규 mad 뉴클레아제 |
| US10704033B1 (en) | 2019-12-13 | 2020-07-07 | Inscripta, Inc. | Nucleic acid-guided nucleases |
| CA3157127A1 (en) | 2019-12-18 | 2021-06-24 | Aamir MIR | Cascade/dcas3 complementation assays for in vivo detection of nucleic acid-guided nuclease edited cells |
| US10689669B1 (en) | 2020-01-11 | 2020-06-23 | Inscripta, Inc. | Automated multi-module cell processing methods, instruments, and systems |
| KR20220133257A (ko) | 2020-01-27 | 2022-10-04 | 인스크립타 인코포레이티드 | 전기천공 모듈 및 기구 |
| US20210332388A1 (en) | 2020-04-24 | 2021-10-28 | Inscripta, Inc. | Compositions, methods, modules and instruments for automated nucleic acid-guided nuclease editing in mammalian cells |
| AU2021265124A1 (en) | 2020-04-27 | 2022-11-03 | Genovie Ab | Methods to generate vaccine compositions that prime human leukocyte antigen class I restricted CD8 T-cell responses against viral non-virion-integral derived epitopes |
| US11787841B2 (en) | 2020-05-19 | 2023-10-17 | Inscripta, Inc. | Rationally-designed mutations to the thrA gene for enhanced lysine production in E. coli |
| WO2022060749A1 (en) | 2020-09-15 | 2022-03-24 | Inscripta, Inc. | Crispr editing to embed nucleic acid landing pads into genomes of live cells |
| US11512297B2 (en) | 2020-11-09 | 2022-11-29 | Inscripta, Inc. | Affinity tag for recombination protein recruitment |
| CA3204158A1 (en) | 2021-01-04 | 2022-07-07 | Juhan Kim | Mad nucleases |
| US11332742B1 (en) | 2021-01-07 | 2022-05-17 | Inscripta, Inc. | Mad nucleases |
| US11884924B2 (en) | 2021-02-16 | 2024-01-30 | Inscripta, Inc. | Dual strand nucleic acid-guided nickase editing |
| CN116286982B (zh) * | 2022-09-09 | 2024-01-30 | 广州凯普医药科技有限公司 | 一种hpv基因分型检测阳性参考品及其制备方法和应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR960701988A (ko) * | 1993-04-20 | 1996-03-28 | 윌리엄 에스. 로빈슨 | 세포내 감염원에 감염된 개체의 치료방법 및 치료물질(methods and materials for treatment of individuals infected with intracellular in-fectious agents) |
| AU2002365938A1 (en) * | 2001-11-20 | 2003-09-02 | Dana-Farber Cancer Institute | Modified antigen-presenting cells |
| EP2982766B1 (en) * | 2010-08-06 | 2018-05-23 | Ludwig-Maximilians-Universität München | Identification of t cell target antigens |
| JP6126804B2 (ja) * | 2012-07-25 | 2017-05-10 | 国立大学法人富山大学 | T細胞受容体のクローニング方法 |
| EP2975942B1 (en) * | 2013-03-21 | 2018-08-08 | Sangamo Therapeutics, Inc. | Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases |
| KR20170075785A (ko) * | 2014-11-05 | 2017-07-03 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 유전자 변형된 면역 효과기 세포 및 면역 효과기 세포의 증식용 가공된 세포 |
| CN105316362B (zh) * | 2015-08-19 | 2020-03-17 | 暨南大学 | 一种Dual-RMCE介导的TCR基因置换系统及其方法 |
-
2017
- 2017-11-07 JP JP2019546065A patent/JP7582779B2/ja active Active
- 2017-11-07 KR KR1020197013903A patent/KR102606929B1/ko active Active
- 2017-11-07 CA CA3039422A patent/CA3039422A1/en active Pending
- 2017-11-07 EP EP17801380.1A patent/EP3535290B1/en active Active
- 2017-11-07 EP EP24150943.9A patent/EP4365296A3/en active Pending
- 2017-11-07 ES ES17801380T patent/ES2970535T3/es active Active
- 2017-11-07 FI FIEP17801380.1T patent/FI3535290T3/fi active
- 2017-11-07 EP EP24150956.1A patent/EP4332226A3/en active Pending
- 2017-11-07 WO PCT/EP2017/078474 patent/WO2018083339A1/en not_active Ceased
- 2017-11-07 CN CN201780068529.9A patent/CN110036026B/zh active Active
- 2017-11-07 DK DK17801380.1T patent/DK3535290T5/da active
- 2017-11-07 LT LTEPPCT/EP2017/078474T patent/LT3535290T/lt unknown
- 2017-11-07 US US16/347,716 patent/US20200115432A1/en not_active Abandoned
- 2017-11-07 AU AU2017352661A patent/AU2017352661B2/en active Active
-
2022
- 2022-12-02 JP JP2022193613A patent/JP2023027162A/ja active Pending
-
2023
- 2023-05-19 US US18/320,900 patent/US20230322896A1/en active Pending
- 2023-12-22 AU AU2023285984A patent/AU2023285984B2/en active Active
- 2023-12-22 AU AU2023285982A patent/AU2023285982B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017352661A1 (en) | 2019-06-13 |
| FI3535290T3 (fi) | 2024-02-05 |
| AU2023285982B2 (en) | 2026-03-12 |
| JP2020513249A (ja) | 2020-05-14 |
| WO2018083339A1 (en) | 2018-05-11 |
| US20200115432A1 (en) | 2020-04-16 |
| EP4365296A3 (en) | 2024-07-24 |
| EP3535290B1 (en) | 2024-01-10 |
| CN110036026A (zh) | 2019-07-19 |
| LT3535290T (lt) | 2024-02-12 |
| EP4365296A2 (en) | 2024-05-08 |
| NZ753806A (en) | 2023-10-27 |
| KR20190076993A (ko) | 2019-07-02 |
| EP4332226A2 (en) | 2024-03-06 |
| EP4332226A3 (en) | 2024-05-08 |
| EP3535290A1 (en) | 2019-09-11 |
| JP7582779B2 (ja) | 2024-11-13 |
| AU2023285984B2 (en) | 2026-03-12 |
| US20230322896A1 (en) | 2023-10-12 |
| KR102606929B1 (ko) | 2023-11-27 |
| AU2023285982A1 (en) | 2024-02-01 |
| AU2023285984A1 (en) | 2024-02-01 |
| CA3039422A1 (en) | 2018-05-11 |
| ES2970535T3 (es) | 2024-05-29 |
| JP2023027162A (ja) | 2023-03-01 |
| AU2017352661B2 (en) | 2023-09-28 |
| DK3535290T5 (da) | 2024-09-02 |
| CN110036026B (zh) | 2024-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3535290T5 (da) | Manipuleret todelt celleindretning til opdagelse og karakterisering af t-celle-receptorinteraktion med beslægtet antigen | |
| DK3384046T3 (da) | Digitalt mikrofluidisk system til enkeltcelleisolering og karakterisering af analytter | |
| EP3564266A4 (en) | NEW CHIMERA RECEIVER OF ANTIGEN AND CORRESPONDING USE | |
| DK3183505T3 (da) | Underlag til positionering af varmeelementer og gulvanlæg | |
| DK3399985T3 (da) | Sammensætninger og biblioteker, der omfatter rekombinante T-cellereceptorer, og fremgangsmåder til anvendelse af rekombinante T-cellereceptorer | |
| DK3551660T3 (da) | Anti-ctla-4-antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3365364T3 (da) | Kimære antistof/T-celle-receptorkonstruktioner og anvendelser deraf | |
| DK3166968T3 (da) | Sammensætninger og fremgangsmåder til kimæriske autoantistofreceptor-T-celler | |
| DK3183880T3 (da) | Samling af intra-blok-kopi og interprædiktion | |
| DK3233289T3 (da) | Anordning til sønderdeling af biologisk materiale og tilsvarende fremstillingsfremgangsmåde og fremgangsmåde til fremstilling af cellesuspensioner og vævsmikrotransplantater | |
| DK3347377T3 (da) | Tymisk stromal lymfopoietin (TSLP)-bindende antistoffer og fremgangsmåder til anvendelse af antistofferne | |
| IL299926A (en) | Neoantigens and methods of their use | |
| DK3148579T3 (da) | Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf | |
| DK3250610T3 (da) | Fcrn-antistoffer og fremgangsmåder til anvendelse heraf | |
| DK3328038T3 (da) | Fremgangsmåde og system til load balancering af anycast-datatrafik | |
| DK4234711T3 (da) | Fremgangsmåder og materialer til vurdering af mangel på homolog rekombination | |
| DK3402483T3 (da) | Fremgangsmåder og sammensætninger til aktivering af gamma-delta-T-celler | |
| DK3300745T3 (da) | Kimærisk antigenreceptor og fremgangsmåder til anvendelse deraf | |
| DK3160964T3 (da) | Arylreceptormodulatorer og fremgangsmåder til fremstilling og brug af samme | |
| DK3222754T3 (da) | Apparat til fremstilling af organisk hydrid og fremgangsmåde til fremstilling af organisk hydrid under anvendelse deraf | |
| DK3519572T3 (da) | Forbindelser og fremgangsmåder til reduktion af tau-ekspression | |
| DK3036588T3 (da) | Forbedringer af elektriske varmesystemer og fremgangsmåde til anvendelse deraf | |
| DK2962753T3 (da) | Hydrogenbehandlingskatalysator med høj densitet af molybden og fremgangsmåde til fremstilling heraf | |
| DK3792628T3 (da) | Fremgangsmåder til forudsigelse af neoantigeners anvendelighed til immunterapi | |
| DK3280839T3 (da) | Indretning til fremføring og spredning af stofstykker |